芬尼酮在俄罗斯慢性肾病和2型糖尿病患者中的应用前景多学科解决方案。咨询委员会

IF 0.7 Q4 ENDOCRINOLOGY & METABOLISM
Diabetes Mellitus Pub Date : 2023-09-25 DOI:10.14341/dm13020
M. V. Shestakova, V. A. Dobronravov, A. S. Ametov, M. B. Antsiferov, M. M. Batyushin, I. N. Bobkova, G. R. Galstyan, T. Y. Demidova, V. V. Klimontov, A. M. Mkrtumyan, N. A. Petunina, E. I. Prokopenko, N. V. Chebotareva, M. S. Shamkhalova
{"title":"芬尼酮在俄罗斯慢性肾病和2型糖尿病患者中的应用前景多学科解决方案。咨询委员会","authors":"M. V. Shestakova, V. A. Dobronravov, A. S. Ametov, M. B. Antsiferov, M. M. Batyushin, I. N. Bobkova, G. R. Galstyan, T. Y. Demidova, V. V. Klimontov, A. M. Mkrtumyan, N. A. Petunina, E. I. Prokopenko, N. V. Chebotareva, M. S. Shamkhalova","doi":"10.14341/dm13020","DOIUrl":null,"url":null,"abstract":"Chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) is one of the most important medical and social problems associated with significant risks for patients and a burden on the national healthcare system. There are significant unmet diagnostic and therapeutic needs of CKD in T2D patients in Russia relating to problems of underdiagnostics of CKD and substantial residual cardiorenal risks in these patients in spite of therapy with registered renoprotective medications. Finerenone is the first selective non-steroidal mineralocorticoid receptor antagonist which targets different from other drugs pathways involved in the pathogenesis of CKD in T2D. It has a significant potential to reduce residual renal and CV risks, and therefore addresses the existing therapeutic unmet need. According to the results of recent clinical studies, the cardio- and renoprotective effects of finerenone were apparent throughout a wide range of CKD C1-C4 in T2D patients, regardless of the severity of kidney dysfunction, the level of HbA1c and other drug therapy. This document summarizes the main results regarding the efficacy and safety profiles of finerenone and determines its place in treatment of CKD in T2D patients.","PeriodicalId":11327,"journal":{"name":"Diabetes Mellitus","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board\",\"authors\":\"M. V. Shestakova, V. A. Dobronravov, A. S. Ametov, M. B. Antsiferov, M. M. Batyushin, I. N. Bobkova, G. R. Galstyan, T. Y. Demidova, V. V. Klimontov, A. M. Mkrtumyan, N. A. Petunina, E. I. Prokopenko, N. V. Chebotareva, M. S. Shamkhalova\",\"doi\":\"10.14341/dm13020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) is one of the most important medical and social problems associated with significant risks for patients and a burden on the national healthcare system. There are significant unmet diagnostic and therapeutic needs of CKD in T2D patients in Russia relating to problems of underdiagnostics of CKD and substantial residual cardiorenal risks in these patients in spite of therapy with registered renoprotective medications. Finerenone is the first selective non-steroidal mineralocorticoid receptor antagonist which targets different from other drugs pathways involved in the pathogenesis of CKD in T2D. It has a significant potential to reduce residual renal and CV risks, and therefore addresses the existing therapeutic unmet need. According to the results of recent clinical studies, the cardio- and renoprotective effects of finerenone were apparent throughout a wide range of CKD C1-C4 in T2D patients, regardless of the severity of kidney dysfunction, the level of HbA1c and other drug therapy. This document summarizes the main results regarding the efficacy and safety profiles of finerenone and determines its place in treatment of CKD in T2D patients.\",\"PeriodicalId\":11327,\"journal\":{\"name\":\"Diabetes Mellitus\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes Mellitus\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14341/dm13020\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Mellitus","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14341/dm13020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

2型糖尿病(T2D)患者的慢性肾脏疾病(CKD)是最重要的医学和社会问题之一,对患者具有重大风险,也是国家卫生保健系统的负担。在俄罗斯,尽管使用了注册的肾脏保护药物治疗,但t2dm患者的CKD诊断和治疗需求仍未得到满足,这与CKD诊断不足的问题和大量残留的心肾风险有关。芬芬烯酮是第一个选择性非甾体类矿皮质激素受体拮抗剂,其作用靶点不同于其他药物参与CKD在T2D中的发病途径。它具有显著的降低残留肾脏和心血管风险的潜力,因此解决了现有治疗未满足的需求。根据最近的临床研究结果,在大范围的CKD C1-C4 T2D患者中,芬尼酮的心脏和肾脏保护作用是明显的,与肾功能障碍的严重程度、HbA1c水平和其他药物治疗无关。本文总结了关于芬尼酮的疗效和安全性的主要结果,并确定了其在治疗t2dm患者CKD中的地位。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board
Chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) is one of the most important medical and social problems associated with significant risks for patients and a burden on the national healthcare system. There are significant unmet diagnostic and therapeutic needs of CKD in T2D patients in Russia relating to problems of underdiagnostics of CKD and substantial residual cardiorenal risks in these patients in spite of therapy with registered renoprotective medications. Finerenone is the first selective non-steroidal mineralocorticoid receptor antagonist which targets different from other drugs pathways involved in the pathogenesis of CKD in T2D. It has a significant potential to reduce residual renal and CV risks, and therefore addresses the existing therapeutic unmet need. According to the results of recent clinical studies, the cardio- and renoprotective effects of finerenone were apparent throughout a wide range of CKD C1-C4 in T2D patients, regardless of the severity of kidney dysfunction, the level of HbA1c and other drug therapy. This document summarizes the main results regarding the efficacy and safety profiles of finerenone and determines its place in treatment of CKD in T2D patients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetes Mellitus
Diabetes Mellitus ENDOCRINOLOGY & METABOLISM-
CiteScore
1.90
自引率
40.00%
发文量
61
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信